Kidney and Bladder Complications of Hematopoietic Cell Transplantation

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 1473-1486

  Hingorani, Sangeeta ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

BK nephropathy; Bladder complications after HCT hemorrhagic cystitis; Chronic kidney disease; Clinical syndromes of CKD after HCT; Hepatic SOS; Immunosuppressive agents immunosuppressive agents and CKD; Kidney and Bladder Complications of Hematopoietic Cell Transplantation; Management of AKI; Nephrotoxic medications

Indexed keywords

EID: 84890711581     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch97     Document Type: Chapter

References (159)

1. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144: 407-14.
2. Zager RA, O'Quigley J, Zager B et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989; 13: 210-16.
3. Hingorani S, Guthrie K, Batchelder A et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int 2005; 67: 272-7.
4. Caliskan Y, Besisik SK, Sargin D, Ecder T. Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation. Bone Marrow Transplant 2006; 38: 141-7.
5. Parikh CR, McSweeney P, Schrier RW. Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int 2005; 67: 1999-2005.
6. Gruss E, Bernis C, Tomas JF et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol 1995; 15: 473-9.
7. Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 1996; 50: 1026-31.
8. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-14.
9. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-8.
10. Letourneau I, Dorval M, Belanger R, Legare M, Fortier L, Leblanc M. Acute renal failure in bone marrow transplant patients admitted to the intensive care unit. Nephron 2002; 90: 408-12.
11. Parikh CR, Schrier RW, Storer B et al. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 2005; 45: 502-9.
12. Parikh CR, McSweeney P, Korular D et al. Renal dysfunction in allogeneic hematopoietic cell transplant. Kidney Int 2002; 62: 566-73.
13. Parikh CR, Sandmaier BM, Storb RF et al. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol 2004; 15: 1868-76.
14. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365: 417-30.
15. Star RA. Treatment of acute renal failure. Kidney Int 1998; 54: 1817-31.
16. McDonald GB, Hinds MS, Fisher LD et al. Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-67.
17. Michael M, Kuehnle I, Goldstein SL. Fluid overload and acute renal failure in pediatric stem cell transplant patients. Pediatr Nephrol 2004; 19: 91-5.
18. Butler W, Bennett J, Alling D. Nephrotoxicity of amphotericin B, early and late effects in 81 patients. Ann Intern Med 1964; 61: 175-87.
19. Harbarth S, Burke J, Lloyd J, Evans S. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002; 35: 120-7.
20. Bates D, Su L, Yu D et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-93.
21. Wingard JR. Bacterial infections. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic Cell Transplant, 3rd edn. Malden: Blackwell Science; 2004. pp. 665-82.
22. Walsh T, Finberg R, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-71.
23. Prentice H, Hann I, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Hematol 1997; 98(3-I): 711-18.
24. Sorkine P, Nagar H, Weinbroum A et al. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity. Crit Care Med 1996; 24: 1311-15.
25. Chalandon Y, Roosnek E, Mermillod B et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347-54.
26. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-12.
27. Cohen E, Lawton C, Moulder J. Bone marrow transplant nephropathy: radiation nephritis revisited. Nephron 1995; 70: 217-22.
28. Hingorani S, Guthrie KA, Schoch G, Weiss NS, McDonald GB. Chronic kidney disease in longterm survivors of hematopoietic cell transplant. Bone Marrow Transplant 2007; 39: 223-9.
29. Weiss AS, Sandamaier BM, Storer B, Storb R, McSweeney P, Parikh CR. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant 2006; 6: 89-94.
30. Tarbell N, Guinan E, Neimeyer C, Mauch P, Sallan S, Weinstein H. Late onset of renal dysfunction in survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys 1988; 15: 99-104.
31. Cogan M, Arieff A. Radiation nephritis and intravascular coagulation. Clin Nephrol 1978; 10: 74-8.
32. Bergstein J, Andreoli S, Provisor A, Yum M. Radiation nephritis following total-body irradiation and cyclophosphamide in preparation for bone marrow transplantation. Transplantation 1986; 41: 63-6.
33. Steele B, Lirenman D. Acute radiation nephritis and the hemolytic uremic syndrome. Clin Nephrol 1979; 11: 272-4.
34. Pettitt A, Clark R. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 494-504.
35. Kist-van Holthe J, van Zwet J, Brand R, van Weel M, Vossen J, van der Heijden A. Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT. Bone Marrow Transplant 1998; 22: 559-64.
36. Moake J. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-99.
37. Fuge R, Bird J, Fraser A et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Hematol 2001; 113: 58-64.
38. Paquette R, Tran L, Landaw E. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant 1998; 22: 351-7.
39. Uderzo C, Fumagalli M, De Lorenzo P et al. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1005-9.
40. Nakamae H, Yamane T, Hasegawa T et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006; 81: 525-31.
41. Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I, Nagler A. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced. Biol Blood Marrow Transplant 2004; 10: 484-93.
42. Ho V, Cutler C, Carter S et al. Blood and marrow transplant Clinical Trials Network Toxicity Committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571-5.
43. Zeigler Z, Shadduck R, Nemunaitis J, Andrews D, Rosenfeld C. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 1995; 15: 247-53.
44. Antignac C, Gubler M-C, Leverger G, Broyer M, Habib R. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int 1989; 35: 1336-44.
45. Lawton C, Cohen E, Murray K et al. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. Bone Marrow Transplant 1997; 20: 1069-74.
46. Schriber J, Herzig G. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997; 42: 126-33.
47. Atkinson K, Biggs J, Hayes J et al. Cyclosporine A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Hematol 1983; 54: 59-67.
48. Zeigler Z, Rosenfeld C, Andrews D, III et al. Plasma von Willebrand factor antigen (vWF:AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura/hemolytic uremic syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). Am J Hematol 1996; 52: 213-20.
49. Chappell M, Keeling D, Prentice H, Sweny P. Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?. Bone Marrow Transplant 1988; 3: 339-47.
50. Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L et al. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transfusion 2003; 43: 78-84.
51. Hahn T, Alam A, Lawrence D et al. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with doseintensive myeloablative conditioning regimens, unrelated donor and methylprednisolone T-cell depletion. Transplantation 2004; 78: 1515-22.
52. Daly AS, Hasegawa WS, Lipton JH, Messner HA, Kiss TL. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versushost disease and venoocclusive disease of the liver. Transfus Apher Sci 2002; 27: 3-12.
53. Uderzo C, Bonanomi S, Busca A et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006; 82: 638-44.
54. Oran B, Donato M, Aleman A et al. Transplantassociated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 2007; 13: 469-77.
55. Marshall R, Sweny P. Haemolytic-uraemic syndrome in recipients of bone marrow transplants not treated with cyclosporine A. Histopathology 1986; 10: 953-62.
56. Fassas AbT, Buddharaju L, Rapoport A et al. Fatal disseminated adenoviral infection associated with thrombotic thrombocytopenic purpura after allogeneic bone marrow transplantation. Leuk Lymphoma 2001; 42: 801-4.
57. Rubin P, Casarett G. Clinical Radiation Pathology. Philadelphia: WB Saunders; 1968.
58. Robbins M, Bonsib S. Radiation nephropathy: a review. Scanning Microsc 1995; 9: 535-60.
59. Cohen E. Radiation nephropathy after bone marrow transplantation. Kidney Int 2000; 58: 903-18.
60. De Gowin R, Lewis L, Hoak J, Mueller A, Gibson D. Radiosensitivity of human endothelial cells in culture. J Lab Clin Med 1974; 84: 42-8.
61. Tannock I, Hayashi S. The proliferation of capillary endothelial cells. Cancer Res 1972; 32: 77-82.
62. Miralbell R, Bieri S, Mermillad B et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol 1996; 14: 579-85.
63. Lonnerholm G, Carlson K, Bratteby L et al. Renal function after autologous bone marrow transplantation. Bone Marrow Transplant 1991; 8: 129-34.
64. Hebert M, Fish D, Madore F et al. Mesangiolysis associated with bone marrow transplantation: new insights on possible etiogenic factors. Am J Kidney Dis 1994; 23: 882-3.
65. Shulman H, Striker G, Deeg H, Kennedy M, Storb R, Thomas E. Nephrotoxicity of cyclosporine A after allogeneic marrow transplantation. N Engl J Med 1981; 305: 1392-5.
66. Perico N, Ruggenenti P, Gaspari F et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992; 54: 56-60.
67. Myers BD, Sibley R, Newton L et al. The longterm course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590-600.
68. Hornung T, de Goede C, O'Brien C, Moghal N, Dark J, O'Sullivan J. Renal function after pediatric cardiac transplantation: the effect of early cyclosporine dosage. Pediatrics 2001; 107: 1346-50.
69. Rubel J, Milford E, McKay D, Jarcho J. Renal insufficiency and end-stage renal disease in the heart transplant population. J Heart Lung Transplant 2004; 23: 289-300.
70. Ojo A, Held P, Port K et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-40.
71. Cutler C, Henry NL, Magee C et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551-7.
72. Guinan E, Tarbell N, Niemeyer C, Sallan S, Weinstein H. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood 1988; 72: 451-5.
73. Fogo A. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000; 35: 179-88.
74. Verheij M, Stewart F, Oussoren Y, Weening J, Dewit L. Amelioration of radiation nephropathy by acetylsalicylic acid. Int J Radiat Biol 1995; 67: 587-96.
75. Nurnberger W, Michelmann I, Burdach S, Gobel U. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998; 76: 61-5.
76. Anthony M, Zeigler Z, Lister J et al. Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation. Am J Hematol 1998; 59: 9-14.
77. Salat C, Holler E, Reinhardt B et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 1994; 14: 747-50.
78. Oikawa T, Freeman M, Lo W, Vaughan D, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51: 164-72.
79. Chandler W, Jelacic S, Boster D et al. Prothrombotic coagulation abnormalities during Escherichia coli 0157:H7 infections. N Engl J Med 2002; 346: 23-32.
80. Chant I, Milford D, Rose P. Plasminogen activator inhibitor activity in diarrhea-associated hemolytic uraemic syndrome. Q J Med 1994; 87: 737-40.
81. Biedermann BC, Sahner S, Gregor M et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359: 2078-83.
82. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cellderived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100-6.
83. Seeber C, Hiller E, Holler E, Kolb HJ. Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF alpha)-release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT). Thromb Res 1992; 66: 373-83.
84. Berg U, Bolme P. Renal function in children following bone marrow transplantation. Transplant Proc 1989; 21: 3092-4.
85. Van Why S, Friedman A, Wei L, Hong R. Renal insufficiency after bone marrow transplantation in children. Bone Marrow Transplant 1991; 7: 383-8.
86. Cohen E, Piering W, Kabler-Babbitt C, Moulder J. End-stage renal disease (ESRD) after bone marrow transplantation: poor survival compared to other causes of ESRD. Nephron 1998; 79: 408-12.
87. Rao P. Nephrotic syndrome in patients with peripheral blood stem cell transplant. Am J Kidney Dis 2005; 45: 780-5.
88. Brukamp K, Doyle A, Bloom R, Bunin N, Tomaszewski J, Cizman B. Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease?. Clin J Am Soc Nephrol 2006; 1: 685-94.
89. Chan GS-W, Lam M, Au W et al. IgA nephropathy complicating graft-vs-host disease, another nephropathy causing nephrotic syndrome after bone marrow transplantation. Histopathology 2004; 45: 642-56.
90. Oliveira J, Bahia D, Franco M, Balda C, Stella S, Kerbauy J. Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal. Bone Marrow Transplant 1999; 23: 99-101.
91. Suehiro T, Masutani K, Yokoyama M et al. Diffuse proliferative glomerulonephritis after bone marrow transplantation. Clinical Nephrol 2002; 58: 231-7.
92. Nouri-Majelan N, Sanadgol H, Ghafari A, Rahimian M, Mortazavizadeh M, Moghaddasi S. Antineutrophil cytoplasmic antibody-associated glomerulonephritis in chronic graft-versus-host disease after allogenic hematopoietic stem cell transplantation. Transplant Proc 2005; 37: 3213-15.
93. Chien Y-H, Lin K-H, Lee T-Y, Lu M-Y, Tsau Y-K. Nephrotic syndrome in a bone marrow transplant recipient without chronic graft versus host disease. J Formos Med Assoc 2000; 99: 503-6.
94. Reddy P, Johnson K, Uberti JP et al. Nephrotic syndrome associated with chronic graft-versushost disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 351-7.
95. Miralbell R, Sancho G, Bieri S et al. Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment. Int J Radiat Oncology Biol Phys 2004; 58: 809-16.
96. Kist-van Holthe J, Goedvolk C, Brand R et al. Prospective study of renal insufficiency after bone marrow transplantation. Pedatric Nephrol 2002; 17: 1032-7.
97. Ferrara J. Pathogenesis of acute graft versus-host disease: cytokines and cellular effectors. J Hematother Stem Cell Res 2000; 9: 299-306.
98. El Seisi S, Gupta R, Clase C, Forrest D, Milandinovic M, Couban S. Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2003; 9: 683-8.
99. Romagnani P, Lazzeri EL, Guidi S, Bosi A, Cirami C, Salvadori M. Nephrotic syndrome and renal failure after allogeneic stem cell transplantation: novel molecular diagnostic tools for a challenging differential diagnosis. Am J Kidney Dis 2005; 46: 550-6.
100. Niculescu F, Niculescu T, Nguyen P et al. Both apoptosis and complement membrane attack complex deposition are major features of murine acute graft vs. host disease. Exp Mol Pathol 2005; 79: 136-45.
101. Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004; 101: 1936-46.
102. Krenger W, Hill G, Ferrara J. Cytokine cascades in acute graft-versus-host disease. Transplantation 1997; 64: 553-8.
103. Takatsuka H, Takemoto Y, Yamada S et al. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant 2000; 26: 419-26.
104. Seconi J, Watt V, Ritchie DS. Nephrotic syndrome following allogeneic stem cell transplantation associated with increased production of TNFalpha and interferon-gamma by donor T cells. Bone Marrow Transplant 2003; 32: 447-50.
105. Teshima T, Ordermann R, Reddy P et al. Acute graft-versus-host disease does not require alloan tigen expression on host epithelium. Nat Med 2002; 8: 575-81.
106. Kansu E. The pathophysiology of chronic graftversus-host disease. Int J Hematol 2004; 79: 209-15.
107. Kitamura K, Suto T. TGF-beta and glomerulonephritis: anti-inflammatory versus prosclerotic actions. Nephrol Dial Transplant 1997; 12: 669-79.
108. Negri A. Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents. J Nephrol 2004; 17: 496-503.
109. Langham R. Transforming growth factor beta1 and tumor growth factor beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 2001; 72: 1826-9.
110. Disel U, Paydas S, Dogan A, Gulfiliz G, Yavuz S. Effect of colchicine on cyclosporine nephrotoxicity, reduction of TGF-beta overexpression, apoptosis, and oxidative damage: an experimental animal study. Transplant Proc 2004; 36: 1372-6.
111. Russo LM, Sandoval RM, McKee M et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int 2007; 71: 504-13.
112. Hilliard L, Russo L, Comper W. Insights into the relationship between hypertension and albuminuria. Curr Hypertens Rev 2007; 3: 29-37.
113. Hingorani S, Seidel K, Aneja T, Schoch G, Lindner A, McDonald G. Albuminuria in hematopoietic cell transplant (HCT) patients: prevalence and risk factors. J Am Soc Nephrol 2006; 17: 405A.
114. Barnett AH, Bain SC, Bouter P et al. Angiotensinreceptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-61.
115. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. Br Med J 2004; 329: 828.
116. Christidou F, Athanasiadou A, Kalogiannidis P et al. Therapeutic plasma exchange in patients with grade 2-3 hematopoietic stem cell transplantation-associated thrombotic thrombocytopenic purpura: a ten year experience. Ther Apher Dial 2003; 7: 259-62.
117. Bosch T, Buhmann R, Lennertz A, Samtleben W, Kolb H. Therapeutic plasma exchange in patients suffering from thrombotic microangiopathy after allogeneic marrow transplantation. Ther Apher 1999; 3: 294-7.
118. Au WY, Ma ES, Lee TL et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 2007; 137: 475-8.
119. Corti P, Uderzo C, Tagliabue A et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 2002; 29: 542-3.
120. Geraci J, Sun M-C, Mariano M. Amelioration of radiation nephropathy in rats by postirradiation treatment with dexamethasone and/or captopril. Radiat Res 1995; 143: 58-68.
121. Juncos L, Carrasco Duenas S, Cornejo J, Broglia C, Cejas H. Long-term enalapril and hydrochlorothiazide in radiation nephritis. Nephron 1993; 64: 249-55.
122. Thomas S, Hutchinson R, DebRoy M, Magee J. Successful renal transplantation following prior bone marrow transplantation in pediatric patients. Pediatr Transplant 2004; 8: 507-12.
123. Butcher J, Hariharan S, Adams M, Johnson C, Roza A, Cohen E. Renal transplantation for endstage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin Transplant 1999; 13: 330-5.
124. Hamawi K, Magalhaes-Silverman M, Bertolatus J. Outcomes of renal transplantation following bone marrow transplantation. Am J Transplant 2003; 3: 301-5.
125. Russell SJ, Vowels MR, Vale T. Haemorrhagic cystitis in paediatric bone marrow transplant patients: an association with infective agents, GVHD and prior cyclophosphamide. Bone Marrow Transplant 1994; 13: 533-9.
126. Tsuboi K, Kishi K, Ohmachi K et al. Multivariate analysis of risk factors for hemorrhagic cystitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 903-7.
127. Sencer SF, Haake RJ, Weisdorf DJ. Hemorrhagic cystitis after bone marrow transplantation. Risk factors and complications. Transplantation 1993; 56: 875-9.
128. Erard V, Storer B, Corey L et al. BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis. Clin Infect Dis 2004; 39: 1861-5.
129. Iwamoto S, Azuma E, Hori H et al. BK virusassociated fatal renal failure following late-onset hemorrhagic cystitis in an unrelated bone marrow transplantation. Pediatr Hematol Oncol 2002; 19: 255-61.
130. Wong AS, Chan KH, Cheng VC, Yuen KY, Kwong YL, Leung AY. Relationship of pretransplantation polyoma BK virus serologic findings and BK viral reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2007; 44: 830-7.
131. Runde V, Ross S, Trenschel R et al. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant 2001; 28: 51-7.
132. Bruno B, Zager R, Boeckh M et al. Adenovirus nephritis in hematopoietic stem-cell transplant. Transplantation 2004; 77: 1049-57.
133. Mori K, Yoshihara T, Nishimura Y et al. Acute renal failure due to adenovirus-associated obstructive uropathy and necrotizing tubulointerstitial nephritis in a bone marrow transplant recipient. Bone Marrow Transplant 2003; 31: 1173-6.
134. Kondo M, Kojima S, Kato K, Matsuyama T. Lateonset hemorrhagic cystitis after hematopoietic stem cell transplantation in children. Bone Marrow Transplant 1998; 22: 995-8.
135. Leung A, Mak R, Lie A et al. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow Transplant 2002; 29: 509-13.
136. Hale GA, Rochester RJ, Heslop HE et al. Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. Biol Blood Marrow Transplant 2003; 9: 698-705.
137. Bedi A, Miller CB, Hanson JL et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995; 13: 1103-9.
138. Shepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips GL. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991; 9: 2016-20.
139. Ballen KK, Becker P, Levebvre K et al. Safety and cost of hyperhydration for the prevention of hemorrhagic cystitis in bone marrow transplant recipients. Oncology 1999; 57: 287-92.
140. Vose JM, Reed EC, Pippert GC et al. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 1993; 11: 1306-10.
141. Hatakeyama N, Suzuki N, Kudoh T, Hori T, Mizue N, Tsutsumi H. Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant. Pediatr Infect Dis J 2003; 22: 928-9.
142. Held TK, Biel SS, Nitsche A et al. Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir. Bone Marrow Transplant 2000; 26: 347-50.
143. Fanourgiakis P, Georgala A, Vekemans M et al. Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. Clin Infect Dis 2005; 40: 199-201.
144. Yusuf U, Hale GA, Carr J et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81: 1398-404.
145. Andrei G, Fiten P, Goubau P et al. Dual infection with polyomavirus BK and acyclovir-resistant herpes simplex virus successfully treated with cidofovir in a bone marrow transplant recipient. Transpl Infect Dis 2007; 9: 126-31.
146. Savona MR, Newton D, Frame D, Levine JE, Mineishi S, Kaul DR. Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 39: 783-7.
147. Leung AY, Yuen KY, Kwong YL. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. Bone Marrow Transplant 2005; 36: 929-37.
148. Leung AY, Wong AS, Chan GC, Yuen KY, Kwong YL. Urinary reactivation of polyoma BK virus but not adenovirus in paediatric and adolescent patients after haematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 621-3.
149. Miodosky M, Abdul-Hai A, Tsirigotis P et al. Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate. Bone Marrow Transplant 2006; 38: 507-11.
150. Laszlo D, Bosi A, Guidi S et al. Prostaglandin E2 bladder instillation for the treatment of hemorrhagic cystitis after allogeneic bone marrow transplantation. Haematologica 1995; 80: 421-5.
151. Cheuk DK, Lee TL, Chiang AK, Ha SY, Lau YL, Chan GC. Risk factors and treatment of hemorrhagic cystitis in children who underwent hematopoietic stem cell transplantation. Transpl Int 2007; 20: 73-81.
152. Miyamura K, Hamaguchi M, Taji H et al. Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. Bone Marrow Transplant 2000; 25: 545-8.
153. Karimi M, Zakerinia M, Khojasteh HN, Ramzi M, Ahmad E. Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven) after allogenic bone marrow transplantation. J Thromb Haemost 2004; 2: 1853-5.
154. Gine E, Rovira M, Real I et al. Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries. Bone Marrow Transplant 2003; 31: 923-5.
155. Koc S, Hagglund H, Ireton RC, Perez-Simon JA, Collins SJ, Appelbaum FR. Successful treatment of severe hemorrhagic cystitis with cystectomy following matched donor allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2000; 26: 899-901.
156. Hattori K, Yabe M, Matsumoto M et al. Successful hyperbaric oxygen treatment of lifethreatening hemorrhagic cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 27: 1315-17.
157. Limaye AP, Smith KD, Cook L et al. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant 2005; 5: 614-20.
158. Tagliabue A, Vallinoto C, Corti P et al. Ureteral obstruction following allogeneic bone marrow transplantation in children. Pediatr Hematol Oncol 2003; 20: 257-60.
159. McCarville MB, Hoffer FA, Gingrich JR, Jenkins JJ, 3rd. Imaging findings of hemorrhagic cystitis in pediatric oncology patients. Pediatr Radiol 2000; 30: 131-8.